Flexion Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Flexion Therapeutics generated cash of -$70,561,000, which is more than the previous year. Cash used in financing activities reached the amount of $118,775,000 last year. Net change in cash is therefore $25,451,000.
Cash Flow
| 2011 | -10.35M | -4.10M | 13M |
|---|---|---|---|
| 2012 | -13.97M | -9.53M | 32.99M |
| 2013 | -16.18M | 15.64M | 3.89M |
| 2014 | -23.14M | -49.45M | 159.50M |
| 2015 | -38.94M | -13.24M | 12.03M |
| 2016 | -62.47M | -132.75M | 163.19M |
| 2017 | -107.83M | -118.79M | 323.49M |
| 2018 | -160.41M | 125.58M | -6.32M |
| 2019 | -148.75M | 114.76M | 29.01M |
| 2020 | -70.56M | -22.76M | 118.77M |
FLXN Cash Flow Statement (2011 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 82.25M | 87.22M | 128.38M | 30.91M | 62.94M | 103.09M | 16.18M | 12.83M | 3.35M | 4.80M |
Operating activities | ||||||||||
Net income | -113.70M | -149.77M | -169.65M | -137.48M | -71.89M | -46.31M | -27.31M | -18.18M | -14.98M | -11.44M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 3.34M | 2.39M | 1.71M | 2.00M | 1.15M | 238.15K | 120.34K | 79.80K | 43.23K | 105.57K |
Stock-based compensation expense | 18.57M | 15.90M | 15.45M | 11.54M | 6.76M | 4.58M | 2.45M | 996.16K | 96.27K | 83.19K |
| Deferred income tax benefit | 18.57M | 15.90M | 15.45M | 11.54M | 6.76M | 4.58M | 2.45M | 996.16K | 96.27K | 83.19K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 7.09M | -23.99M | -12.71M | -410K | 95.28K | 0 | 0 | 0 | 0 | 0 |
Inventories | -922K | -7.67M | -5.24M | -1.79M | 2.76M | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -6.56M | 1.70M | 5.14M | 4.18M | -992.73K | 1.58M | 518.03K | 475.82K | -176.27K | 507.24K |
Cash generated by operating activities | -70.56M | -148.75M | -160.41M | -107.83M | -62.47M | -38.94M | -23.14M | -16.18M | -13.97M | -10.35M |
Investing activities | ||||||||||
Purchases Of Investments | -79.61M | -115.46M | -222.48M | -356.75M | -196.06M | -145.79M | -79.38M | -15.01M | -28.46M | -16.81M |
Investments In Property Plant And Equipment | -10.06M | -3.89M | -852K | -2.14M | -8.43M | -5.19M | -802.48K | -405.31K | -34.91K | -39.53K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -22.76M | 114.76M | 125.58M | -118.79M | -132.75M | -13.24M | -49.45M | 15.64M | -9.53M | -4.10M |
Financing activities | ||||||||||
Common Stock Issued | 97.28M | 0 | 0 | 132.66M | 147.88M | 0 | 162.13M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -15M | 0 | -10M | 0 | 0 | 0 | -1.5M | 0 | 0 | 0 |
Cash used in financing activities | 118.77M | 29.01M | -6.32M | 323.49M | 163.19M | 12.03M | 159.50M | 3.89M | 32.99M | 13M |
Net Change In Cash | 25.45M | -4.97M | -41.16M | 96.87M | -32.02M | -40.15M | 86.90M | 3.35M | 9.47M | -1.45M |
Cash at end of period | 107.70M | 82.25M | 87.22M | 127.78M | 30.91M | 62.94M | 103.09M | 16.18M | 12.83M | 3.35M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |